RenovaCare’s Scientific Affairs Officer Transitions to Chief Scientific Officer Role

RenovaCare Inc., developer of patented technologies for spraying self-donated stem cells for the regeneration of skin and other organs and tissues, announced that its vice president, Scientific Affairs, Dr. Robin A. Robinson, will now serve in a new and expanded full-time role as the company’s chief scientific officer. Prior to joining RenovaCare, Dr. Robinson served as founding Director of the Biomedical Advanced Research and Development Authority (BARDA) that leads development and stockpiling of medical countermeasures for national preparedness and response to man-made threats, pandemic influenza, and emerging infectious agents.
 
“With Dr. Robinson now full time at the helm of our science, research and development programs, along with the support of our scientific and engineering teams, we continue enhancing our capabilities and uncovering cell-spray breakthroughs to enable first-in-class regenerative therapies,” stated Alan L. Rubino, CEO and president of RenovaCare Inc.
 
Dr. Robinson joins the executive management team and is responsible for setting the scientific strategy and priorities and leading R&D at RenovaCare. He will also interface with the intellectual property group for new products innovation and development, and with the company’s regulatory teams to advance its U.S. Food and Drug Administration (FDA) submission pathway. Dr. Robinson will additionally chair the RenovaCare Scientific Advisory Board.
 
“From the beginning, I’ve been impressed by the scientific integrity and therapeutic promise of RenovaCare innovative cell isolation and spray therapy technologies for burns and wounds. Looking ahead, the prospect of isolating multiple cell types from many tissues for ultra-gentle spray administration using our patented SkinGun, unlocks compelling clinical indications that may extend far beyond the regeneration of skin,” stated Robinson. 
 
“Dr. Robinson brings us seasoned managerial capabilities along with extensive depth of knowledge and experience with tissue regeneration and cell-based therapies for thermal and radiation burns, deep tissue wounds, and diabetic ulcers. He is also  a respected authority, with special insights into product development, regulatory affairs, and breakthrough biomedical technologies,” concluded Rubino.
 
Notably, during his prior tenure at BARDA, Dr. Robinson concurrently served as deputy assistant secretary, U.S. Department of Health and Human Services. He brought BARDA into prominence as one of the top 10 fully integrated R&D organizations worldwide supporting advanced development and acquisition of more than 240 drugs, vaccines, diagnostics, and medical devices by industry partners with 38 approved and licensed by the FDA during his 12-year tenure. He led the nation’s medical countermeasure efforts against the avian influenza H5N1 threat (2004-2008), the H1N1 pandemic (2009), Ebola epidemic (2014), and Zika epidemic (2015). For these efforts, he was recognized in 2018 as one of the top 100 Champions for Change in medicine by the Medicine Maker.
 
During his tenure at BARDA, Dr. Robinson oversaw the support for development of many stem cell and other therapies for thermal and radiation burn wounds and acute radiation syndrome illnesses.  
 
Prior to his appointment as RenovaCare chief scientific officer, Dr. Robinson served as vice president of Scientific Affairs at the company in a part-time consulting capacity since August 2019. As chief scientific officer, Dr. Robinson joins the executive leadership team in a full time position, with substantially expanded research and development responsibilities at RenovaCare.
 
Over 70 patients with various types of second-degree burns have been treated on an experimental basis utilizing the technology underlying the company’s SkinGun and CellMist System, which RenovaCare has developed as a potential alternative to skin grafting and other treatment options. Sprayed with a gentle mist of their own skin cells, many of these patients left the hospital within days, avoiding generally painful skin graft surgeries and potentially prolonged hospitalization.